This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05660642
Recruitment Status : Recruiting
First Posted : December 21, 2022
Last Update Posted : March 30, 2023
Sponsor:
Information provided by (Responsible Party):
Beckley Psytech Limited

Brief Summary:
An open-label, multi-centre, Phase 2a study to evaluate the safety, tolerability and pharmacodynamics after a single intranasal dose of BPL-003 combined with psychological support, in patients with treatment resistant depression not currently taking antidepressants.

Condition or disease Intervention/treatment Phase
Treatment Resistant Depression Drug: BPL-003 Phase 2

Detailed Description:
Approximately 12 eligible participants will be receive a single dose of BPL-003, given intranasally, with 12 weeks of follow-up assessments. Psychological support will be given before, during and after dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase 2a, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Actual Study Start Date : February 10, 2023
Estimated Primary Completion Date : October 2023
Estimated Study Completion Date : October 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BPL-003 arm Drug: BPL-003
Single dose administered intranasally




Primary Outcome Measures :
  1. To assess the safety and tolerability of a single intranasal dose of BPL-003 in patients with treatment resistant depression [ Time Frame: Baseline to 12 weeks post dose ]
    • Percentage of patients with treatment emergent adverse events
    • Percentage of patients with clinically significant abnormal laboratory tests
    • Percentage of patients with clinically significant abnormal vital signs
    • Percentage of patients with clinically significant findings in physical examination
    • Percentage of patients with clinically significant ECG parameters
    • Percentage of patients with suicidal ideation or behavior


Other Outcome Measures:
  1. Change from Baseline in MADRS [ Time Frame: Day 2 to 12 weeks post dose ]
  2. Percentage of responders [ Time Frame: Day 2 to 12 weeks post dose ]
    Defined as 50% reduction in MADRS score compared to Baseline

  3. Percentage of patients in remission [ Time Frame: Day 2 to 12 weeks post dose ]
    Defined as MADRS score of <11

  4. Plasma levels of 5-MeO-DMT and its metabolite (bufotenine) [ Time Frame: Day 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosed with Major Depressive Disorder.
  2. Diagnosed with TRD defined as failure to respond to an adequate dose and duration of at least 2 pharmacological treatments.
  3. Montgomery-Asberg Depression Rating Scale score ≥24 at Screening.
  4. Clinical Global Impression - Severity ≥4 at Screening.
  5. Quick Inventory of Depressive Symptomatology - Self Rated - 16 item scale ≥13 at Screening.
  6. Willing and able to discontinue current pharmacological anti-depressant therapy.

Exclusion Criteria:

  1. Current or history of schizophrenia, psychotic disorder including psychotic depression, bipolar disorder, delusional disorder, schizoaffective disorder, or any other severe psychiatric disorder.
  2. Current personality disorders.
  3. First-degree family history of schizophrenia, bipolar disorder, delusional disorder, personality disorders or schizoaffective disorder.
  4. Current alcohol or substance use disorder (other than caffeine or nicotine).
  5. A participant who at any time, has been unresponsive to ketamine, esketamine, an adequate course of treatment with electroconvulsive therapy, or has received vagal nerve stimulation or deep brain stimulation.
  6. Suicidal ideation or behavior within the 12 months prior to the start of Screening or on Day 1 prior to dosing.
  7. Suicide attempt and/or self-injurious behavior within the last 12 months prior to Screening.
  8. Uncontrolled medical conditions e.g. hypo/hyperthyroidism, diabetes, renal failure.
  9. Seizure disorder or history of seizures (including febrile seizures).
  10. Abnormal and clinically significant results on the physical examination, vital signs, electrocardiogram, or laboratory tests at Screening Baseline.
  11. Any nasal obstruction, blockage, or symptoms of congestion at the time of dosing, that in the Investigator's opinion may interfere with administration of the study drug.
  12. Currently receiving lithium, antipsychotics, serotonergic drugs, psychostimulants, or any other prohibited medication.
  13. Female patients who are pregnant or lactating, or of childbearing potential and not willing to use adequate forms of contraception.
  14. Male patients who are sexually active and not willing to using adequate forms of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05660642


Contacts
Layout table for location contacts
Contact: Beckley Psytech Ltd +44 (0)1865 987633 Medinfo@beckleypsytech.com

Locations
Layout table for location information
United Kingdom
Hammersmith Medicines Research Recruiting
London, United Kingdom
Contact: Study Coordinator    +44 (0)20 8961 4130    REC@hmrlondon.com   
King's College London, Clinical Trials Facility Recruiting
London, United Kingdom
Contact: Clinical Trials Facility       5-meo-dmt@kcl.ac.uk   
Sponsors and Collaborators
Beckley Psytech Limited
Investigators
Layout table for investigator information
Study Director: Chief Medical Officer, MD, PhD Beckley Psytech Ltd
Layout table for additonal information
Responsible Party: Beckley Psytech Limited
ClinicalTrials.gov Identifier: NCT05660642    
Other Study ID Numbers: BPL-003-204
First Posted: December 21, 2022    Key Record Dates
Last Update Posted: March 30, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders